APTABIO THERAPEUTICS
AptaBio Therapeutics is a pharmaceutical biotechnology company that develops intractable innovative drugs.
APTABIO THERAPEUTICS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2009-01-01
Address:
Giheung, Kyonggi-do, South Korea
Country:
South Korea
Website Url:
http://www.aptabio.com
Total Employee:
11+
Status:
Active
Contact:
+82 31-365-3693
Total Funding:
31.8 B KRW
Technology used in webpage:
IPhone / Mobile Compatible Euro Content Delivery Network Mobile Non Scaleable Content ReCAPTCHA Pound Sterling ReCAPTCHA V2 Japanese Yen UNPKG ReCAPTCHA V3
Similar Organizations
AION Labs
AION Labs creates AI and computational technologies that transforms drug discovery.
AL Biotech
AL Biotech is a biotechnology company that develops biopharmaceutical drugs.
Amtix Bio
Amtix Bio is a biotechnology company that develops drugs to treat microbial infectious diseases and related diseases.
AULBIO
AULBIO is a research-intensive biotechnology company that develops and commercialization of biopharmaceutical products.
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Jixing Pharmaceuticals
Jixing Pharmaceuticals develops innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases.
Investors List
Samsung Securities
Samsung Securities investment in Series B - AptaBio Therapeutics
Midas Doang-A Investment
Midas Doang-A Investment investment in Series B - AptaBio Therapeutics
IBK Capital
IBK Capital investment in Series B - AptaBio Therapeutics
Synergy IB Investment
Synergy IB Investment investment in Series B - AptaBio Therapeutics
Shinhan Investment
Shinhan Investment investment in Series B - AptaBio Therapeutics
GMB Investment
GMB Investment investment in Series B - AptaBio Therapeutics
LB Investment
LB Investment investment in Series B - AptaBio Therapeutics
Kolon Investment
Kolon Investment investment in Series A - AptaBio Therapeutics
HB Investment
HB Investment investment in Venture Round - AptaBio Therapeutics
Official Site Inspections
http://www.aptabio.com Semrush global rank: 5.52 M Semrush visits lastest month: 1.32 K
- Host name: 112.175.85.237
- IP address: 112.175.85.237
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "AptaBio Therapeutics"
AptaBio Therapeutics - Crunchbase Company Profile
AptaBio Therapeutics closed its last funding round on May 15, 2018 from a Series B round. Who are AptaBio Therapeutics 's competitors? Alternatives and โฆSee details»
AptaBio Co., Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Aptabio's Isuzinaxib (APX-115) prove s its effect on a key kidney function marker in a Phase 2 clinical study in patients with diabetes and chronic kidney disease. Isuzinaxib (APX-115) is a โฆSee details»
AptaBio - Products, Competitors, Financials, Employees, โฆ
AptaBio is a company that specializes in the development of first-in-class drugs based on platform technology, operating in the pharmaceutical industry. Use the CB Insights Platform to explore โฆSee details»
AptaBio
ํ๋ซํผ ๊ธฐ์ ๊ธฐ๋ฐ First-in-Class. ์ ์ฝ๊ฐ๋ฐ ์ ๋ฌธ ๊ธฐ์ ์ํ๋ฐ์ด์ค๋ ๋ ์ฐฝ์ ์ธ ํ๋ซํผ ๊ธฐ์ ์ ๋ฐํ์ผ๋ก ๋์น์ฑ ์งํ์ ๋ํ First-in-Class ํ์ ์ ์ฝ์ ๊ฐ๋ฐํ๋ ์ ์ฝ๋ฐ์ด์ค ๊ธฐ์ ์ผ๋ก 2009๋ ์ โฆSee details»
AptaBio Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 AptaBio. Stock Price. โฉ8.4 K. 2024-10-29. Market Capitalization. โฉ185.7 B. 2024-10-29. AptaBio Summary. Company Summary. Overview. AptaBio is a biopharmaceutical โฆSee details»
Aptabio Therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Aptabio Therapeutics Inc. of Yongin, Gyeonggi. Get the latest business insights from Dun & Bradstreet.See details»
AptaBio Therapeutics - Funding, Financials, Valuation & Investors
AptaBio Therapeutics is a pharmaceutical biotechnology company that develops intractable innovative drugs. Search Crunchbase. Start Free Trial . Chrome Extension. ... How much โฆSee details»
Aptabio Therapeutics - Overview, News & Similar companies
Nov 3, 2022 Who is Aptabio Therapeutics. AptaBio is a South Korean pharmaceutical company at the forefront of discovery and development of selective inhibitors of the NOX family of โฆSee details»
AptaBio Therapeutics Company Description - Stock Analysis
Oct 11, 2024 AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, โฆSee details»
AptaBio Therapeutics - Tech Stack, Apps, Patents & Trademarks
Nov 10, 2024 Organization. AptaBio Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech โฆSee details»
Aptabio Company Profile 2024: Stock Performance & Earnings
Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti โฆSee details»
AptaBio Therapeutics Inc. (293780.KQ) - Yahoo Finance
See the company profile for AptaBio Therapeutics Inc. (293780.KQ) including business summary, industry/sector information, number of employees, business summary, corporate governance, โฆSee details»
AptaBio
Nov 4, 2022 Aptabio's Isuzinaxib (APX-115) proves its effect on a key kidney function marker in a Phase 2 clinical study in patients with diabetes and chronic kidney disease.. Isuzinaxib (APX โฆSee details»
Aptabio Therapeutics - VentureRadar
Similar Companies: GEn1E Lifesciences USA Privately Held GEn1E Lifesciences Inc. (โGenieโ) is a biotechnology company with a platform for accelerating cures for inflammatory and age โฆSee details»
AptaBio Therapeutics Inc - Company Profile and News
Company profile page for AptaBio Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
AptaBio Therapeutics - Crunchbase
Companies like AptaBio Therapeutics include Jixing Pharmaceuticals, AULBIO, and Enzyvant Sciences. Enzyvant Sciences Basel , Basel-Stadt , Switzerland 48 Contacts 11-50 employeesSee details»
293780 Stock Price Quote | Morningstar
Nov 29, 2024 Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer โฆSee details»
Aptabio to initiate Phase II oral Covid-19 therapy trial
Mar 26, 2021 Aptabio intends to conclude a confirmatory clinical trial based upon positive results from the Phase II trial and will submit an application seeking emergency use authorization. In a โฆSee details»
AptaBio Therapeutics (293780 KS): Promising, Innovative
Nov 5, 2021 AptaBio Therapeutics (293780 KS) shares surged 28% in last one month, increasing its one-year gain to 213% versus KOSPIโs gain of 26%. Share price was driven by โฆSee details»